Rodolfo Bordoni

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.

James R. Berenson, Alan Lichtenstein, Lisa A. Porter et al. · Journal of Clinical Oncology · 1998 · 653 citations

Medicine, Pharmacology, Pharmacotherapy +14

Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial

Makoto Nishio, Fabrice Barlési, Howard West et al. · Journal of Thoracic Oncology · 2020 · 458 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Andres Forero‐Torres, Beata Holkova, Jerome H. Goldschmidt et al. · Blood · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

OA05.07 IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC

Vassiliki A. Papadimitrakopoulou, Manuel Cobo, Rodolfo Bordoni et al. · Journal of Thoracic Oncology · 2018 · 120 citations · Full text

Medicine, Oncology, Pharmacology +10

Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Joachim von Pawel, Rodolfo Bordoni, Miyako Satouchi et al. · European Journal of Cancer · 2018 · 106 citations

Medicine, Oncology, Pharmacotherapy +12